Julian Blagg is Vice President Drug Discovery and SAB Chairperson at NeoPhore Ltd, a small molecule immuno-oncology company. He is an experienced medicinal chemist and oncology drug discovery scientist. Prior to joining NeoPhore, he was Deputy Director, Professor and Head of Chemistry at the Cancer Research UK Cancer Therapeutics Unit at the Institute of Cancer Research (ICR), London, UK from 2007 to 2018. Before joining ICR, Julian practiced medicinal chemistry and drug discovery in the pharmaceutical industry (Pfizer), both in the US and UK, where he was responsible for the discovery and progression of multiple preclinical development candidates into clinical trials across 4 therapeutic areas. With colleagues from the ICR, Julian was recipient of the 2012 American Association of Cancer Research (AACR) Team Science Award for achievements in drug discovery and served as Chair of the Chemistry in Cancer Research section of the AACR from 2018-2019. He is a fellow of the Royal Society of Chemistry and has authored over 200 publications and patents.